

Essential regulatory practice in the development of novel therapies

24 November 2020 | 5-6 pm (CET) | SPARK-BIH Online Lecture

5 pm **Essential regulatory practice in the development of novel therapies**

Dr. Gabriele Dallmann

Consultant for approval of new medicines and
co-founder of *Biopharma Excellence GmbH*

Which regulatory aspects are crucial to translate a new drug candidate into early clinical development?

In this **Online Educational Forum Lecture**, **Dr. Gabriele Dallmann** will help you to understand regulatory requirements as well as experimental testing of medicines for successful drug development. Dr. Dallmann is an ex-regulator who has worked at Committees of the European Medicines Agency (EMA) and at the Paul-Ehrlich-Institut (PEI) where she was in charge of the approval of antibody-containing products and has been involved in the assessment of other product classes of biopharmaceuticals including ATMPs.

Online via [GoToMeeting](#) | Please register [here](#).

>> spark-bih.de
>> bihealth.org

SPARK-BIH is an initiative created at Stanford University, to overcome challenges associated with translation of academic discoveries.